The BD Phoenix™ system offers a variety of identification only, susceptibility only and combination identification and susceptibility panels. BD Phoenix™ panels provide accurate, rapid identification and susceptibility results for most clinically significant aerobic and facultative anaerobic Gram-negative and Gram-positive bacteria, as well as identification of yeast and yeast-like organisms.
- Overview
- Applications
- Products & Accessories
- EIFU & Resources
true
Trusted performance
The BD Phoenix™ system provides on-panel doubling dilutions and built-in detection resistance, including CPO, MRSA, mecA, VRSA, VRE, ESBL, HLAR, and iMLSb*.
Ease of use
BD Phoenix™ panels can be stored at room temperature, are leak-resistant and do not require reagent additions post inoculation.
Emerging resistance detection
The BD Phoenix™ Emerge™ Gram-negative and Gram-positive panels offer 136 wells for susceptibility testing, allowing for additional antimicrobial dilutions that help provide the foundation for detecting emerging resistance.
Detecting Carbapenamase producing organisms (CPOs)
The BD Phoenix™ CPO detect test, offered on certain Gram-negative panels, provides information, including Ambler classification, to clinicians to help guide their treatment decisions.
Dual growth detection technology
BD Phoenix™ panels allow the BD Phoenix™ M50 instrument to determine growth using both an oxidation-reduction reaction and turbidity development, providing both rapid and accurate susceptibility results.
True doubling dilutions
The BD Phoenix™ system utilizes on-panel doubling dilutions of antimicrobial concentrations for determination of MIC results.
Multiple panel formats
BD Phoenix™ panels, which require no refrigeration and are leak resistant, are available in a variety of formats including identification-only and susceptibility-only, and in combination identification and susceptibility panels.
Largest number of wells per panel
With 136 wells dedicated to susceptibility testing, the BD Phoenix™ Emerge™ panel may allow for additional antimicrobial dilutions or additional drugs.
Resistance detection
The BD Phoenix™ system provides on-panel doubling dilutions of antimicrobials and built-in detection of resistance, including CPO, MRSA, mecA, VRSA, VRE, ESBL, HLAR, and iMLSb*.
*Depending on BD Phoenix™ panel type and organism identification.
Automated panel inoculation preparation
The BD Phoenix™ AP automated inoculation preparation instrument may help to reduce sample preparation workflow burdens, reducing total hands-on time per sample by 50% compared to manual BD Phoenix™ preparation and by an average of 20% compared to selected competitive products.1-2
- The BD Phoenix™ system offers identification-only panels and combination ID/AST panels, using 51 wells for identification substrates.
- The instrument can provide rapid identification of most clinically significant Gram-negative and Gram- positive bacteria, as well as yeast.
- The BD Phoenix™ system offers 85 wells for antimicrobial dilutions on standard AST-only panels and combination ID/AST panels, and 136 wells on the BD Phoenix™ Emerge™ panel.
- The instrument can provide rapid susceptibility results for most clinically significant Gram-negative and Gram-positive bacteria.
- The BD Phoenix™ system panels test for several resistance markers*such as**:
- Gram-positive bacteria
- HLAR—High Level Aminoglycoside Resistant Enterococcus
- iMLSb—Inducible Clindamycin Resistance
- MRSA—based on Oxacillin Interpretation with Staphylococcus species
- mecA - detection in mecA-mediated resistance Staphylococcus Aureus
- BL-Staphylococcus ß-Lactamase (Nitrocefin-based test)
- VRSA—Vancomycin-Resistant Staphylococcus Aureus
- VRE—based on Vancomycin interpretation
- Gram-negative bacteria
- CPO—Carbapenemase Producing Organism
- ESBL—offered on Gram-negative panels and requires no additional disc diffusion or E-Test confirmation
- Gram-positive bacteria
* Depending on BD Phoenix™ panel type and organism identification.
- The BD Phoenix™ CPO detect test, available on certain BD Phoenix™ Gram-negative panels, provides information, including Ambler classification, to help guide clinicians in their treatment decisions.
- This test is available in two-panel configurations that allow microbiology labs to test for CPOs as part of routine susceptibility testing on BD Phoenix™ panels:
- 2-well configuration—provides detection of Carbapenemase-producing organisms in Enterobacteriaceae, Pseudomonas aeruginosa and Acinetobacter baumannii
- 9-well configuration—provides detection of Carbapenemase-producing organisms and Ambler classification (A, B or D) in Enterobacteriaceae, Pseudomonas aeruginosa and Acinetobacter baumannii
- The BD Phoenix™ CPO detect test is currently the only phenotypic test on an automated AST system that provides CPO detection and Ambler classification.
- On average, the BD Phoenix™ CPO detect test detects and classifies CPOs from isolated colonies within 6 to 11 hours**.
**BD internal studies—data on file
Literature
BD's collection of literature on industry and on our offerings gives you information you can use to continue striving for excellence.
Learn more
Training
BD offers training resources to help improve your clinical practices as part of our goal of advancing the world of health.
Learn more
Events
BD supports the healthcare industry with market-leading products and services that aim to improve care while lowering costs. We host and take part in events that excel in advancing the world of health™.
Learn more
Case Studies
BD promotes clinical excellence by providing various resources on best practices, clinical innovations and industry trends in healthcare.
Learn more
false
Notes
- Junkins A, et al. Comparison of BD Phoenix™ AP Workflow with Vitek 2. J. Clin. Microbiol. 2010. 48 (5): 1929-1931. – Study was a supported grant from BD Diagnostic Systems
- Jungkind D, et al. Workflow evaluation of the BD Phoenix™ AP Compared to the MicroScan Walkaway overnight system for identification and susceptibility testing of bacteria. As presented at the 110th General Meeting of the American Society of Microbiology. May 2010. – Study was a supported grant from BD Diagnostic Systems
true
